The Clinical Characteristics of ARDS in Children With Hematological Neoplasms.
acute respiratory distress syndrome
agranulocytosis
children
clinical characteristics
hematological neoplasms
Journal
Frontiers in pediatrics
ISSN: 2296-2360
Titre abrégé: Front Pediatr
Pays: Switzerland
ID NLM: 101615492
Informations de publication
Date de publication:
2021
2021
Historique:
received:
19
04
2021
accepted:
31
05
2021
entrez:
26
7
2021
pubmed:
27
7
2021
medline:
27
7
2021
Statut:
epublish
Résumé
In order to explore the clinical characteristics of pediatric patients admitted to the pediatric intensive care unit (PICU) who suffered from hematological neoplasms complicated with acute respiratory distress syndrome (ARDS), we retrospectively analyzed 45 ARDS children with hematological neoplasms who were admitted to the PICU of Shanghai Children's Medical Center from January 1, 2014, to December 31, 2020. The 45 children were divided into a survival group and a non-survival group, a pulmonary ARDS group and an exogenous pulmonary ARDS group, and an agranulocytosis group and a non-agranulocytosis group, for statistical analysis. The main clinical manifestations were fever, cough, progressive dyspnea, and hypoxemia; 55.6% (25/45) of the children had multiple organ dysfunction syndrome (MODS). The overall mortality rate was 55.6% (25/45). The vasoactive inotropic score (VIS), pediatric critical illness scoring (PCIS), average fluid volume in the first 3 days and the first 7 days, and the incidence of MODS in the non-survival group were all significantly higher than those in the survival group (
Identifiants
pubmed: 34307258
doi: 10.3389/fped.2021.696594
pmc: PMC8295493
doi:
Types de publication
Journal Article
Langues
eng
Pagination
696594Informations de copyright
Copyright © 2021 Zhang, Hu, Yin, Qian, Wang, Li, Qian, Tang and Ning.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Crit Care. 2001 Jun;16(2):54-8
pubmed: 11481599
Pediatr Crit Care Med. 2018 Oct;19(10):e504-e513
pubmed: 30036234
Pediatr Crit Care Med. 2010 Mar;11(2):234-8
pubmed: 19794327
Intensive Care Med. 2009 Jan;35(1):136-43
pubmed: 18825369
Pediatr Crit Care Med. 2017 Aug;18(8):750-757
pubmed: 28486385
Pediatr Pulmonol. 2021 May;56(5):1182-1188
pubmed: 33289279
Intensive Care Med. 2018 Jul;44(7):1050-1060
pubmed: 29881987
Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619887437
pubmed: 31775524
Am J Respir Crit Care Med. 2021 Feb 15;203(4):504-508
pubmed: 32986956
Crit Care. 2009;13(6):R173
pubmed: 19886984
Rev Esp Quimioter. 2019 Sep;32 Suppl 2:55-58
pubmed: 31475812
Zhongguo Dang Dai Er Ke Za Zhi. 2019 Sep;21(9):898-903
pubmed: 31506150
Chest. 2006 Sep;130(3):724-9
pubmed: 16963669
Eur Respir J. 2012 Jul;40(1):169-76
pubmed: 22135281
Chin Med J (Engl). 2012 Jul;125(13):2265-71
pubmed: 22882846
Chest. 2008 Jun;133(6):1463-1473
pubmed: 17989150
J Pediatr Intensive Care. 2015 Sep;4(3):146-155
pubmed: 31110864
J Intensive Care Med. 2019 Jul;34(7):563-571
pubmed: 28460591
Pediatr Pulmonol. 2020 Apr;55(4):1000-1006
pubmed: 32017471
Front Pediatr. 2014 Jul 25;2:78
pubmed: 25121078
Pediatr Crit Care Med. 2015 Jun;16(5):428-39
pubmed: 25647235
Pediatr Clin North Am. 2017 Oct;64(5):1017-1037
pubmed: 28941533
Hematology. 2013 May;18(3):123-30
pubmed: 23321772
PLoS One. 2019 Oct 30;14(10):e0224563
pubmed: 31665179
Crit Care. 2017 Oct 20;21(1):254
pubmed: 29052522
J Intensive Care Med. 2020 Apr;35(4):364-370
pubmed: 29343171
Arch Dis Child. 2018 May;103(5):420-426
pubmed: 29269559
PeerJ. 2015 Feb 10;3:e752
pubmed: 25699202
Respir Care. 2017 Sep;62(9):1178-1185
pubmed: 28559467